# Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina

Study · id `cardio:ct-nct03789552` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03789552](<https://clinicaltrials.gov/study/NCT03789552>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT03789552

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 765 participants.

## Technical summary

Registry record NCT03789552. Randomized; quadruple masking; primary purpose treatment. Start 2019-08-01 (actual); primary completion 2026-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 765 participants (planned count; ClinicalTrials.gov record NCT03789552, source copy `cardio:ctgov-nct03789552-2025-04-09`, retrieved 2026-11-18)
- Started: 2019-08-01 (actual) (ClinicalTrials.gov record NCT03789552, source copy `cardio:ctgov-nct03789552-2025-04-09`, retrieved 2026-11-18)
- Primary completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT03789552, source copy `cardio:ctgov-nct03789552-2025-04-09`, retrieved 2026-11-18)
- Completion: 2027-03 (anticipated) (ClinicalTrials.gov record NCT03789552, source copy `cardio:ctgov-nct03789552-2025-04-09`, retrieved 2026-11-18)
- Countries: United States (ClinicalTrials.gov record NCT03789552, source copy `cardio:ctgov-nct03789552-2025-04-09`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03789552-2025-04-09`, retrieved 2026-11-18)

## The registry's words

- Brief title: Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina
- Condition: Chronic Stable Angina Pectoris
- Intervention (Drug): T89 capsule
- Intervention (Drug): Placebo capsule
- Lead sponsor: Tasly Pharmaceuticals, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Angina pectoris (`cardio:angina-pectoris`)

## Provenance

Content hash: ed400b919044b5576b1ea3ebb336b4476dca5ecb82ee81655c710e1ce5cc3a90
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
